Important Disclosure: Low-dose naltrexone (LDN) is a compounded medication. Compounded medications are not FDA-approved drugs. Naltrexone is FDA-approved at standard doses (50 mg) for specific indications, but compounded low-dose formulations (typically 0.5–4.5 mg) are a distinct category and have not received FDA approval. PepScribe is a telehealth platform that connects patients with licensed clinicians and does not manufacture, compound, or dispense medications. Nothing on this page should be interpreted as a disease claim or a guarantee of specific outcomes.
What Is Low-Dose Naltrexone?
Naltrexone is a small-molecule opioid antagonist that has been used at standard doses (50 mg) since the 1980s. Low-dose naltrexone — commonly abbreviated LDN, refers to the use of naltrexone at significantly lower doses, typically ranging from 0.5 mg to 4.5 mg. At these reduced doses, the pharmacological behavior of naltrexone shifts in ways that have attracted growing interest from researchers and clinicians.
LDN is not a peptide. It is a conventional small-molecule compound. However, it is frequently discussed alongside peptide therapies because it shares a similar access pathway: compounding pharmacies prepare LDN in custom dosages that are not commercially available as manufactured products. Because these compounded formulations are not FDA-approved, access typically requires a clinician's prescription and is filled through a licensed compounding pharmacy.
PepScribe's telehealth platform is designed to help with connecting patients to licensed providers who can evaluate whether LDN may be appropriate based on individual health history and goals.
How Does LDN Work? Understanding the Mechanism of Action
At standard doses (50 mg), naltrexone fully blocks opioid receptors for 24 hours or more. At low doses, the mechanism is believed to be fundamentally different. Here is a simplified overview of the proposed pathways:
Transient Opioid Receptor Blockade
At doses between 1 and 4.5 mg, naltrexone is thought to produce a brief, partial blockade of opioid receptors, lasting only a few hours rather than a full day. This transient blockade may support the body's own endorphin production through a rebound effect. Endorphins play a role in mood regulation, immune modulation, and the body's natural response to discomfort.
Immune System Modulation
One of the most-discussed aspects of LDN's proposed mechanism involves its interaction with toll-like receptor 4 (TLR4) on immune cells, particularly microglia in the central nervous system. Researchers have hypothesized that LDN may support balanced immune signaling by influencing these pathways. This is a structure/function observation, not a disease treatment claim, the research is ongoing and no definitive conclusions have been established for compounded LDN formulations.
Endorphin Upregulation
The brief opioid receptor blockade from LDN is hypothesized to prompt the body to increase production of endogenous opioids (endorphins and enkephalins). These naturally occurring compounds may support general well-being, comfort, and immune function.
Note: These mechanisms are based on published hypotheses and preliminary research. They do not constitute proof of efficacy for any specific condition.
The Research Landscape: What Has Been Studied?
LDN has been the subject of a growing body of preliminary research. It is important to understand the current state of evidence clearly: most studies are small, many are pilot trials, and large-scale randomized controlled trials remain limited. Below is a summary of the areas where LDN has been investigated.
Fibromyalgia
Several small clinical trials have explored LDN in the context of fibromyalgia-related discomfort. Published pilot studies (notably from Stanford University, published in journals such as Pain Medicine) have reported that participants experienced improvements in self-reported quality-of-life measures. These studies were small (typically fewer than 40 participants) and the authors themselves have called for larger confirmatory trials.
LDN may support comfort and recovery in individuals dealing with ongoing physical challenges, but it is not approved or proven to treat fibromyalgia.
Autoimmune-Related Research
Researchers have investigated LDN's potential role in supporting immune system balance. Published case series and small trials have examined LDN in the context of various autoimmune-related concerns. The proposed mechanism, modulation of TLR4 and glial cell activity, provides a theoretical basis for this line of inquiry.
Again, compounded LDN is not FDA-approved for any autoimmune condition, and the existing evidence base consists primarily of preliminary and observational data.
Chronic Fatigue and General Well-Being
Some clinicians and researchers have explored LDN in the context of fatigue and general wellness. Anecdotal reports and small observational studies suggest that some individuals report improvements in energy and daily functioning. These reports are not equivalent to controlled clinical evidence.
LDN may support overall well-being and daily functioning, but no specific outcomes can be promised or guaranteed.
Quality of Life and Mood
Endorphin upregulation, one of LDN's proposed mechanisms, has led some researchers to investigate its potential role in supporting mood and emotional well-being. This remains an area of active investigation with limited controlled data.
Dosing Ranges: What to Expect
LDN dosing is highly individualized and should always be determined by a licensed clinician. The following ranges are provided for educational context only.
| Dose Range | Common Context |
|---|---|
| 0.5 – 1.5 mg | Often used as a starting dose; some clinicians begin here and titrate upward |
| 1.5 – 3.0 mg | Mid-range doses frequently referenced in published literature |
| 3.0 – 4.5 mg | The upper end of what is typically considered "low-dose"; 4.5 mg is the most commonly cited target dose in research |
Titration
Many clinicians prefer a gradual titration approach, starting at a lower dose and increasing over several weeks. This approach is designed to help with minimizing potential adjustment effects such as vivid dreams or mild sleep disruption, which some individuals report during the initial period.
Timing
LDN is most commonly taken at bedtime, based on the hypothesis that the transient opioid receptor blockade aligns with the body's natural endorphin production cycle during sleep. However, some clinicians recommend morning dosing for individuals who experience sleep-related side effects.
Your clinician will determine the appropriate dose, timing, and duration based on your individual health profile.
How Compounding Works for LDN
Because naltrexone is commercially manufactured only in 50 mg tablets (and as an injectable formulation for other uses), obtaining low doses requires compounding. Here is how the process works:
- Clinician Evaluation: A licensed provider evaluates your health history and determines whether LDN may be appropriate.
- Prescription: If appropriate, the clinician writes a prescription for a specific LDN dose.
- Compounding Pharmacy: The prescription is sent to a licensed compounding pharmacy, which prepares the medication in the prescribed dose, typically as a capsule or liquid.
- Dispensing: The compounding pharmacy ships the medication directly to the patient.
Important Compounding Facts
- Compounded medications are prepared by licensed pharmacies but are not FDA-approved products.
- Compounding pharmacies are regulated by state boards of pharmacy and, in some cases, by the FDA under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.
- PepScribe does not manufacture, compound, or dispense any medications. PepScribe is a telehealth platform that facilitates consultations with licensed clinicians.
What Does the Telehealth Consultation Process Look Like?
Accessing LDN through PepScribe follows a straightforward telehealth pathway:
Step 1: Health Intake
You complete a detailed health questionnaire covering your medical history, current medications, health goals, and any relevant lab work. This information is reviewed by a licensed clinician before your consultation.
Step 2: Clinician Consultation
A licensed provider reviews your intake and conducts a telehealth consultation. During this visit, the clinician will:
- Discuss your health goals and concerns
- Evaluate whether LDN may be appropriate for you
- Explain potential benefits, limitations, and side effects
- Answer your questions
Step 3: Prescription (If Appropriate)
If the clinician determines that LDN is a reasonable option, they will write a prescription and coordinate with a licensed compounding pharmacy.
Step 4: Ongoing Support
PepScribe's platform is designed to help with ongoing clinician access for dose adjustments, follow-up questions, and progress monitoring.
Start your consultation
Safety Considerations and Side Effects
LDN is generally considered well-tolerated at low doses based on published literature and clinical experience. However, as with any medication, side effects are possible.
Commonly Reported Side Effects
- Vivid dreams or sleep disturbance, most frequently reported, often transient
- Mild headache, typically resolves within the first few weeks
- Nausea, uncommon, usually mild
- Mood changes, reported infrequently
Contraindications and Precautions
- LDN should not be taken by individuals currently using opioid medications (prescription or otherwise), as it may precipitate withdrawal.
- Individuals with active liver disease should discuss risks with their clinician.
- LDN's safety during pregnancy and breastfeeding has not been established.
- Always disclose all current medications and supplements to your clinician.
Drug Interactions
Because LDN acts on opioid receptors, it may interact with opioid-containing medications, certain immunosuppressants, and other compounds. A thorough medication review is a standard part of the consultation process.
Who May Be a Good Candidate for LDN?
LDN may support individuals who are:
- Interested in exploring immune system support under clinician supervision
- Looking for options that may support comfort and recovery
- Seeking to support overall well-being and daily functioning
- Willing to work with a clinician on a supervised, individualized protocol
LDN is not appropriate for individuals who:
- Are currently taking opioid medications
- Have certain liver conditions (discuss with your clinician)
- Are pregnant or breastfeeding
- Are looking for a guaranteed cure or treatment for a specific disease
The Bottom Line
Low-dose naltrexone is a compounded medication with a growing but still preliminary evidence base. It is not FDA-approved in low-dose formulations, and no specific outcomes can be promised. However, the published research and clinical interest in LDN continue to expand, and many individuals are exploring it under clinician supervision as part of a broader wellness strategy.
PepScribe's telehealth platform is designed to help with connecting you to licensed clinicians who can evaluate whether LDN may be appropriate for your individual situation.
See all available options
PepScribe is a telehealth platform. PepScribe does not manufacture, compound, or dispense medications. All prescriptions are written by independently licensed clinicians and filled by licensed compounding pharmacies. Compounded medications are not FDA-approved drugs.